Pfizer logo

Pfizer

PFE | NYSE
Chart Builder DCF Calculator
$28.86
-$0.03 (-0.10%)
At close: Nov 16, 2026, 4:01 PM ET
$28.86
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:53 PM ET
-0.10%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
32.7
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #724/1021 (Top 71%)

Why Price Moved

4 days ago
-2.11%

Shares are trading lower after Pfizer secured Blac...

Key Statistics

Market Data

Market Cap $164.5B
1D Range
28.81 29.28
52W Range
23.67 30.79

Valuation (TTM)

PE 41.23
PB 1.85
EV/EBITDA 15.81

Valuation (NTM)

Forward PE 9.47
Forward PEG -19.09
Price Target $30.50
Loading financial charts...

Profile

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehe...

Sector Healthcare
Employees 75,000
IPO Date Jun 1, 1972
Fiscal Year January - December

Latest News

5 Dividend Stocks With High Yields That Are Safer Than You Might Think

2 days ago · fool.com

5 Dividend Stocks With High Yields That Are Safer Than You Might Think
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?

2 days ago · fool.com

Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?

2 days ago · fool.com

Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?

3 days ago · fool.com

Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?

3 days ago · zacks.com

Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug

4 days ago · seekingalpha.com

Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity Drug
Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program

4 days ago · zacks.com

Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug

4 days ago · barrons.com

Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss Drug
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development

5 days ago · wsj.com

Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug Development
Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

5 days ago · reuters.com

Pfizer secures up to $1.5 billion from Blackstone for obesity drug development

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.87
Beat +18.37%
REV
$16.58B
Beat +4.61%
Next Earnings
Feb 2, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
13
Consensus
Hold
Price Target
$30.50
Upside
+5.68%
Buy (5)
Hold (8)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.